Homoeopathy in the prevention of COVID-19

Homoeopathic medicines in the prevention of COVID-19 among high risk individuals: A community based, double-blind randomized controlled trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/09/028122

Enrollment

15992

Registered

2020-09-29

Start date

Unknown

Completion date

Unknown

Last updated

2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Arsenicum album 30: Two doses of medicated globules (no. 10) will be given as single dose once in a week for two weeks. The cane sugar globules will be medicated with the medicine (pres

Route of administration: Oral

Duration of therapy: 2 weeks Intervention2: Oscillococcinum® (Anas barbariae hepatis et cordis extractum 200K): Two doses of medicated globules (no. 10) will be given as single dose once in a week for

Duration of therapy: 2 weeks Intervention3: Influenzinum 30: Two doses of medicated globules (no. 10) will be given as single dose once in a week for two weeks. The cane sugar globules will be medicat

Duration of therapy: 2 weeks Control Intervention1: Placebo: This arm, will receive placebo, indistinguishable from verum. Each dose shall consist of 4 globules (no.10) for children aged up to 12 year

Eligibility

Inclusion criteria

Inclusion criteria: a)Persons residing in the ward no. 27 under Howrah Municipal Corporation. d)Person giving consent to participate (guardian’s consent in cases of minors)

Exclusion criteria

Exclusion criteria: a)Diagnosed cases of COVID-19 or persons with related symptoms b)People who have already taken homoeopathic medicines in some forms within the last 15 days c)Cases with vital organ failure d)Immune compromised state

Design outcomes

Primary

Measure	Time frame
Occurrence of newly diagnosed (laboratory confirmed) COVID-19 infection rates across the groupsTimepoint: After 30 days of first medicine intake or once the person reports the tests positive for the same.	—

Secondary

Measure	Time frame
Occurrence of flu like illness and/or clinically suspected cases of COVID-19 infection across the groups.Timepoint: At any time points within 30 days of follow-up	—

Countries

India

Contacts

Public ContactShubhamoy Ghosh

Mahesh Bhattacharyya Homoeopathic Medical College and Hospital

shubhamoy67@gmail.com9831034229

Outcome results